Biomarin Pharmaceutical vs Alnylam Pharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Biomarin Pharmaceutical Inc (BMRN)

Q3 202623 Jun – 30 Sep 2026

▲4

BioMarin advances Voxzogo, adds Alesta, settles patent, raises guidance

Voxzogo nears full FDA approval and $1B revenue Voxzogo moved toward full FDA approval, with a decision expected February 2027, and approached $1 billion in annual revenue. Positive Phase 3 data in hypochondroplasia supports a filing to expand its label.
Voxzogo is BioMarin's key growth driver, and its regulatory and commercial progress directly boosts investor confidence.
Alesta acquisition adds oral hypophosphatasia therapy BioMarin acquired Alesta, gaining ALE1, a potential first oral treatment for hypophosphatasia. The deal expands the pipeline into a new rare disease area, though ALE1 remains unproven.
The acquisition adds a new pipeline asset and strategic growth opportunity, which can lift investor sentiment.
Patent settlement with Ascendis secures royalties BioMarin settled patent litigation with Ascendis, securing royalties on rival Yuviwel through 2030. This removes legal uncertainty and provides a finite but predictable revenue stream.
The settlement eliminates a legal overhang and adds royalty income, improving financial visibility.
Raised guidance and Amicus synergies improve outlook BioMarin raised its financial guidance, targeted $200 million in annual savings from Amicus synergies, and accelerated deleveraging. An AI enzyme partnership with Profluent adds long-term pipeline potential.
These financial and strategic moves strengthen the company's outlook and support the stock.

September 202631 Aug – 30 Sep 2026

▲4

BioMarin settles patent fight, closes Alesta, and expands VOXZOGO

Patent settlement secures royalties on rival Yuviwel BioMarin settled global patent disputes with Ascendis, winning 20% US and 18% EU/Brazil/South Korea royalties on Yuviwel sales through May 2030. This turns a costly legal fight into a steady income stream and removes uncertainty, lifting the stock.
This is the period's biggest new event, directly adding royalty revenue and removing litigation risk.
Alesta acquisition adds oral hypophosphatasia drug BioMarin completed its purchase of Alesta Therapeutics, adding ALE1, a potential first oral therapy for hypophosphatasia, to its pipeline. This strengthens the rare bone disease portfolio and gives investors a new growth candidate beyond existing drugs.
A new pipeline asset expands future revenue potential and shows management is investing in growth.
VOXZOGO nears $1B, Amicus synergies on track VOXZOGO grew patients 20% quarterly and is expected to hit $1 billion in revenue this year, while Amicus integration targets $200 million in annual cost savings and faster debt reduction. Strong sales plus cost cuts boost profits and cash flow.
This shows the core growth driver and merger savings that directly improve earnings and balance sheet.
VOXZOGO hypochondroplasia data and AI enzyme deal BioMarin reported positive Phase 3 results for VOXZOGO in hypochondroplasia and filed for FDA approval, expanding its label. It also partnered with Profluent to use AI to design new enzyme therapies, adding long-term pipeline potential.
New indication and AI partnership broaden the franchise and future pipeline, supporting the growth story.

Latest31 Aug – 30 Sep 2026

▲4

BioMarin settles patent fight, closes Alesta, and expands VOXZOGO

Patent settlement secures royalties on rival Yuviwel BioMarin settled global patent disputes with Ascendis, winning 20% US and 18% EU/Brazil/South Korea royalties on Yuviwel sales through May 2030. This turns a costly legal fight into a steady income stream and removes uncertainty, lifting the stock.
This is the period's biggest new event, directly adding royalty revenue and removing litigation risk.
Alesta acquisition adds oral hypophosphatasia drug BioMarin completed its purchase of Alesta Therapeutics, adding ALE1, a potential first oral therapy for hypophosphatasia, to its pipeline. This strengthens the rare bone disease portfolio and gives investors a new growth candidate beyond existing drugs.
A new pipeline asset expands future revenue potential and shows management is investing in growth.
VOXZOGO nears $1B, Amicus synergies on track VOXZOGO grew patients 20% quarterly and is expected to hit $1 billion in revenue this year, while Amicus integration targets $200 million in annual cost savings and faster debt reduction. Strong sales plus cost cuts boost profits and cash flow.
This shows the core growth driver and merger savings that directly improve earnings and balance sheet.
VOXZOGO hypochondroplasia data and AI enzyme deal BioMarin reported positive Phase 3 results for VOXZOGO in hypochondroplasia and filed for FDA approval, expanding its label. It also partnered with Profluent to use AI to design new enzyme therapies, adding long-term pipeline potential.
New indication and AI partnership broaden the franchise and future pipeline, supporting the growth story.

July 202623 Jun – 18 Aug 2026

▲4

BioMarin's Voxzogo Expansion, Amicus Deal, and Alesta Buy Drive Growth

Voxzogo Regulatory Progress The FDA accepted BioMarin's application for full approval of Voxzogo, with a decision expected by February 2027. This moves the drug closer to broader use, which could boost sales and reassure investors about the company's growth path.
This is a key regulatory milestone that directly affects future revenue from BioMarin's flagship drug.
Raised Guidance and Faster Deleveraging BioMarin raised its 2025 revenue and earnings guidance and now expects to cut debt faster than planned, thanks to the Amicus acquisition. This signals stronger financial health and growth from new products like Galafold and Pombiliti/Opfolda.
It shows improved financial performance and balance sheet strength, which can lift investor confidence and the stock price.
Alesta Acquisition Adds Oral Therapy BioMarin agreed to buy Alesta Therapeutics for $275 million upfront to gain ALE1, a potential first oral treatment for hypophosphatasia. This expands the pipeline into a new disease area with a convenient pill form, which could drive future growth.
It represents a strategic pipeline expansion that may open a new market and diversify revenue.
Sustained Voxzogo Data in Hypochondroplasia New three-year data showed Voxzogo continued to improve growth in children with hypochondroplasia, and BioMarin plans to file for approval in this new use. This could significantly expand the patient population and sales potential.
It supports label expansion into a larger market, directly impacting future revenue growth.

23 Jun – 18 Aug 2026

▲4

BioMarin's Voxzogo Expansion, Amicus Deal, and Alesta Buy Drive Growth

Voxzogo Regulatory Progress The FDA accepted BioMarin's application for full approval of Voxzogo, with a decision expected by February 2027. This moves the drug closer to broader use, which could boost sales and reassure investors about the company's growth path.
This is a key regulatory milestone that directly affects future revenue from BioMarin's flagship drug.
Raised Guidance and Faster Deleveraging BioMarin raised its 2025 revenue and earnings guidance and now expects to cut debt faster than planned, thanks to the Amicus acquisition. This signals stronger financial health and growth from new products like Galafold and Pombiliti/Opfolda.
It shows improved financial performance and balance sheet strength, which can lift investor confidence and the stock price.
Alesta Acquisition Adds Oral Therapy BioMarin agreed to buy Alesta Therapeutics for $275 million upfront to gain ALE1, a potential first oral treatment for hypophosphatasia. This expands the pipeline into a new disease area with a convenient pill form, which could drive future growth.
It represents a strategic pipeline expansion that may open a new market and diversify revenue.
Sustained Voxzogo Data in Hypochondroplasia New three-year data showed Voxzogo continued to improve growth in children with hypochondroplasia, and BioMarin plans to file for approval in this new use. This could significantly expand the patient population and sales potential.
It supports label expansion into a larger market, directly impacting future revenue growth.

Alnylam Pharmaceuticals Inc (ALNY)

Q3 20269 Jul – 31 Jul 2026

▲2▼2

Alnylam's TTR Guidance Cut Triggers 29% Plunge Despite Record Quarter

TTR Guidance Cut Sends Shares Down 29% Alnylam lowered its 2026 TTR revenue guidance to $4.2–4.5 billion from $4.4–4.7 billion, citing slower second-line demand for Amvuttra. The stock plunged 29% as investors feared the flagship franchise's growth is decelerating, overshadowing strong Q2 results.
This is the single biggest new event of the period and the main reason ALNY is moving right now.
Amvuttra Tops $1 Billion in a Quarter for First Time Amvuttra exceeded $1 billion in quarterly sales, with total product revenue up 74% and non-GAAP operating income tripling to $318 million. This shows the drug is still growing strongly, but the guidance cut signals the pace will slow.
It is the key new financial result that contrasts with the guidance cut and explains the mixed market reaction.
Rival ATTR-CM Drug Fails, Boosting Alnylam's Competitive Edge AstraZeneca and Ionis's Wainua failed a Phase 3 ATTR-CM trial, removing a potential competitor. Alnylam shares initially rose 18% as its Amvuttra faces less competition in the cardiomyopathy market, though the later guidance cut reversed those gains.
This is a major new competitive development that initially drove the stock up and remains a positive force.
Securities Fraud Investigation Adds Legal Uncertainty Kirby McInerney launched an investigation into potential securities law violations following the guidance cut. While no lawsuit has been filed, the probe adds uncertainty and could pressure the stock as investors weigh legal risks.
It is a new negative development that could affect investor sentiment and is directly tied to the guidance cut.

July 20269 Jul – 31 Jul 2026

▲2▼2

Alnylam's TTR Guidance Cut Triggers 29% Plunge Despite Record Quarter

TTR Guidance Cut Sends Shares Down 29% Alnylam lowered its 2026 TTR revenue guidance to $4.2–4.5 billion from $4.4–4.7 billion, citing slower second-line demand for Amvuttra. The stock plunged 29% as investors feared the flagship franchise's growth is decelerating, overshadowing strong Q2 results.
This is the single biggest new event of the period and the main reason ALNY is moving right now.
Amvuttra Tops $1 Billion in a Quarter for First Time Amvuttra exceeded $1 billion in quarterly sales, with total product revenue up 74% and non-GAAP operating income tripling to $318 million. This shows the drug is still growing strongly, but the guidance cut signals the pace will slow.
It is the key new financial result that contrasts with the guidance cut and explains the mixed market reaction.
Rival ATTR-CM Drug Fails, Boosting Alnylam's Competitive Edge AstraZeneca and Ionis's Wainua failed a Phase 3 ATTR-CM trial, removing a potential competitor. Alnylam shares initially rose 18% as its Amvuttra faces less competition in the cardiomyopathy market, though the later guidance cut reversed those gains.
This is a major new competitive development that initially drove the stock up and remains a positive force.
Securities Fraud Investigation Adds Legal Uncertainty Kirby McInerney launched an investigation into potential securities law violations following the guidance cut. While no lawsuit has been filed, the probe adds uncertainty and could pressure the stock as investors weigh legal risks.
It is a new negative development that could affect investor sentiment and is directly tied to the guidance cut.

Latest9 Jul – 31 Jul 2026

▲2▼2

Alnylam's TTR Guidance Cut Triggers 29% Plunge Despite Record Quarter

TTR Guidance Cut Sends Shares Down 29% Alnylam lowered its 2026 TTR revenue guidance to $4.2–4.5 billion from $4.4–4.7 billion, citing slower second-line demand for Amvuttra. The stock plunged 29% as investors feared the flagship franchise's growth is decelerating, overshadowing strong Q2 results.
This is the single biggest new event of the period and the main reason ALNY is moving right now.
Amvuttra Tops $1 Billion in a Quarter for First Time Amvuttra exceeded $1 billion in quarterly sales, with total product revenue up 74% and non-GAAP operating income tripling to $318 million. This shows the drug is still growing strongly, but the guidance cut signals the pace will slow.
It is the key new financial result that contrasts with the guidance cut and explains the mixed market reaction.
Rival ATTR-CM Drug Fails, Boosting Alnylam's Competitive Edge AstraZeneca and Ionis's Wainua failed a Phase 3 ATTR-CM trial, removing a potential competitor. Alnylam shares initially rose 18% as its Amvuttra faces less competition in the cardiomyopathy market, though the later guidance cut reversed those gains.
This is a major new competitive development that initially drove the stock up and remains a positive force.
Securities Fraud Investigation Adds Legal Uncertainty Kirby McInerney launched an investigation into potential securities law violations following the guidance cut. While no lawsuit has been filed, the probe adds uncertainty and could pressure the stock as investors weigh legal risks.
It is a new negative development that could affect investor sentiment and is directly tied to the guidance cut.

Q2 202622 Jun – 3 Jul 2026

▲4

Alnylam's RNAi Engine Roars: AI Deals, Regulatory Wins, and a 121% Revenue Surge

Amvuttra's 187% sales jump powers 121% total revenue growth Amvuttra sales soared 187% to $889.9 million, driving total Q1 product revenue up 121% to $1.04 billion. This blockbuster growth is the core reason Alnylam's stock can rebound, as it proves the company's flagship drug is winning in the cardiomyopathy market.
This is the fundamental growth engine behind the stock's potential recovery and analyst optimism.
AI partnerships with Inceptive and Komodo aim to speed drug discovery and commercialization Alnylam formed a $2 billion AI collaboration with Inceptive Nucleics to accelerate RNAi drug discovery and expanded its Komodo Health partnership to scale AI analytics. These deals could shorten development timelines and boost pipeline productivity, supporting long-term growth.
These new AI initiatives signal future pipeline expansion and operational efficiency, key for a biotech's valuation.
Cemdisiran accepted for FDA and EMA review in myasthenia gravis Regulators accepted marketing applications for cemdisiran, with FDA priority review and a November decision date. This milestone brings a potential new rare-disease therapy closer to market, diversifying revenue beyond Amvuttra and adding a near-term catalyst.
A regulatory acceptance is a concrete step toward a new product approval, directly impacting future revenue.
Analysts see 45% upside as Brown Advisory initiates a position Wall Street's average price target is $436, about 45% above the recent close, and Brown Advisory initiated a stake citing an attractive entry point. These votes of confidence suggest the market may be undervaluing Alnylam's growth prospects.
Institutional buying and analyst targets reflect external validation of the company's value after a steep selloff.

June 202622 Jun – 3 Jul 2026

▲4

Alnylam's RNAi Engine Roars: AI Deals, Regulatory Wins, and a 121% Revenue Surge

Amvuttra's 187% sales jump powers 121% total revenue growth Amvuttra sales soared 187% to $889.9 million, driving total Q1 product revenue up 121% to $1.04 billion. This blockbuster growth is the core reason Alnylam's stock can rebound, as it proves the company's flagship drug is winning in the cardiomyopathy market.
This is the fundamental growth engine behind the stock's potential recovery and analyst optimism.
AI partnerships with Inceptive and Komodo aim to speed drug discovery and commercialization Alnylam formed a $2 billion AI collaboration with Inceptive Nucleics to accelerate RNAi drug discovery and expanded its Komodo Health partnership to scale AI analytics. These deals could shorten development timelines and boost pipeline productivity, supporting long-term growth.
These new AI initiatives signal future pipeline expansion and operational efficiency, key for a biotech's valuation.
Cemdisiran accepted for FDA and EMA review in myasthenia gravis Regulators accepted marketing applications for cemdisiran, with FDA priority review and a November decision date. This milestone brings a potential new rare-disease therapy closer to market, diversifying revenue beyond Amvuttra and adding a near-term catalyst.
A regulatory acceptance is a concrete step toward a new product approval, directly impacting future revenue.
Analysts see 45% upside as Brown Advisory initiates a position Wall Street's average price target is $436, about 45% above the recent close, and Brown Advisory initiated a stake citing an attractive entry point. These votes of confidence suggest the market may be undervaluing Alnylam's growth prospects.
Institutional buying and analyst targets reflect external validation of the company's value after a steep selloff.

22 Jun – 3 Jul 2026

▲4

Alnylam's RNAi Engine Roars: AI Deals, Regulatory Wins, and a 121% Revenue Surge

Amvuttra's 187% sales jump powers 121% total revenue growth Amvuttra sales soared 187% to $889.9 million, driving total Q1 product revenue up 121% to $1.04 billion. This blockbuster growth is the core reason Alnylam's stock can rebound, as it proves the company's flagship drug is winning in the cardiomyopathy market.
This is the fundamental growth engine behind the stock's potential recovery and analyst optimism.
AI partnerships with Inceptive and Komodo aim to speed drug discovery and commercialization Alnylam formed a $2 billion AI collaboration with Inceptive Nucleics to accelerate RNAi drug discovery and expanded its Komodo Health partnership to scale AI analytics. These deals could shorten development timelines and boost pipeline productivity, supporting long-term growth.
These new AI initiatives signal future pipeline expansion and operational efficiency, key for a biotech's valuation.
Cemdisiran accepted for FDA and EMA review in myasthenia gravis Regulators accepted marketing applications for cemdisiran, with FDA priority review and a November decision date. This milestone brings a potential new rare-disease therapy closer to market, diversifying revenue beyond Amvuttra and adding a near-term catalyst.
A regulatory acceptance is a concrete step toward a new product approval, directly impacting future revenue.
Analysts see 45% upside as Brown Advisory initiates a position Wall Street's average price target is $436, about 45% above the recent close, and Brown Advisory initiated a stake citing an attractive entry point. These votes of confidence suggest the market may be undervaluing Alnylam's growth prospects.
Institutional buying and analyst targets reflect external validation of the company's value after a steep selloff.